News | Artificial Intelligence | June 08, 2020

With users for clinical and trial in countries such as Italy, France, Portugal, Brazil, Indonesia, Panama, South Korea, etc., Lunit seeks to become a worldwide provider of AI solution in COVID-19 management

Lunit announced that their AI solution for chest x-ray analysis is now being used and tested in more than 10 countries for COVID-19 management, providing assistance in chest X-ray interpretation during patient triage and monitoring.

A radiologist in Hospital do Câncer de Pernambuco, located in Recife, Brazil, is examining a chest x-ray image using Lunit INSIGHT CXR.


June 8, 2020 — Lunit announced that their AI solution for chest x-ray analysis is now being used and tested in more than 10 countries for COVID-19 management, providing assistance in chest X-ray interpretation during patient triage and monitoring.

The firm had released the AI solution in late March, providing the algorithm online to help healthcare providers manage COVID-19. Since then, the firm had deployed its software onsite in more than 10 locations throughout different countries, including Italy, France, Portugal, Brazil, Indonesia, Panama and South Korea.

“Together with our partners, we took a step further from providing the solution online, now actively deploying the AI on-site within the hospitals,” said Brandon Suh, CEO of Lunit. “The actual use of AI within COVID-19 management varies on the independent hospital systems and workflow, but generally the software provides assistance in the interpretation of chest x-ray images during triaging symptomatic patients and monitoring admitted patients with COVID-19.”

Lunit is in partnership with Vizyon, a French teleradiology firm that specializes in providing a platform for AI software by connecting the technology to hospitals. Vizyon is using Lunit AI in analyzing the images they receive from their clients.

“During patient triage, Lunit INSIGHT CXR developed for COVID-19 can accelerate the decision-making of patients with symptoms while awaiting PCR results,” said Pierre Durand, M.D., of Vizyon. When the symptomatic patient shows up to a hospital, the patient is tested with both PCR and AI-assisted chest x-ray, with the latter providing an analysis result in less than 5 minutes. 

“The doctor, upon reviewing the analysis made by AI, can promptly decide whether to send the patient back home or to the Emergency Hospital, depending on the severity. PCR results generally take six to 24 hours, risking a longer window of contamination while awaiting results, a longer gap of treatment, and a possible hospital overload,” Durand added.

Brazil was one of the early adopters of the solution, installed and tested at more than 11 hospitals including PreventSenior, one of the largest hospital networks in Brazil with 8 locations throughout the metropolitan region of Sao Paulo. Now having analyzed more than 30,000 chest x-ray images of COVID-19 cases in the last two months, a physician at PreventSenior said that “Lunit INSIGHT CXR seems to provide great help, especially for patient triage,” as the hospital is overflowing with patients while the number of radiologists remains limited.

In Italy, a country that saw large numbers of COVID-19 cases, Lunit AI is being used in Vimercate hospital, deployed through the company’s partnership with Fujifilm. The COVID-19 crisis has brought a need to improve workflow in the hospital, by easing the burden of reading a mass amount of exams. The hospital is based in Lombardia, Italy, and takes around 160,000 radiology exams in a year with 17 radiologists and 19 technicians. 

AI findings are integrated into the Fujifilm Synapse platform which Vimercate hospital uses for reading radiologic images. According to the hospital, Lunit INSIGHT is used for every chest x-ray analysis, including emergency room patients with respiratory symptoms and patients with COVID-19. It is also used to examine a discharging patient with no symptoms, and to evaluate the feasibility of anesthesia prior to a surgical operation.

The original algorithm of Lunit INSIGHT CXR detects 10 findings from chest x-ray images including consolidation, nodule, pneumothorax, and more. It is CE marked and clinically available in Europe. 

“Among the many hospitals we have been in touch with, many of them were experiencing frustrations from limited PCR tests and/or a lack of manpower and resources,” said Minhong Jang, Chief Business Officer at Lunit. “In hopes of sharing the burden, we are seeking more health facilities where we can provide assistance with advanced technology. We welcome you to learn more about our solution and reach out to better manage the current crisis."

For more information: www.lunit.io


Related Content

News | PACS

July 8, 2026 — Freeland Systems, a cloud PACS and clinical imaging software company, has launched its new customer ...

Time July 10, 2026
arrow
News | Ultrasound Imaging

July 7, 2026 — Longeviti Neuro Solutions has launched a new strategic initiative, ClearFit AI, a Brain Ultrasound ...

Time July 09, 2026
arrow
News | Prostate Cancer

July 8,2026 — CorePlus, Puerto Rico’s fully digital precision pathology and clinical laboratory, has announced the ...

Time July 08, 2026
arrow
News | Women's Health

July 1, 2026 — Despite declining birth rates worldwide, the complexity of pregnancy is increasing. Advanced maternal age ...

Time July 01, 2026
arrow
News | Information Technology

June 26, 2026 — Radin Health recently announced the successful deployment of its cloud-native platform at four ...

Time June 26, 2026
arrow
News | FDA

June 25, 2026 — Aidoc recently announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device ...

Time June 25, 2026
arrow
News | Mammography

June 23, 2026 — Using artificial intelligence (AI), researchers found that image-based risk scores for breast cancer ...

Time June 24, 2026
arrow
News | Pediatric Imaging

June 16, 2026 — Crescom has officially launched a global clinical Proof of Concept (PoC) of its pediatric ...

Time June 24, 2026
arrow
News | Information Technology

June 24, 2026 — HOPPR Presto Agent (Presto) is now commercially available from HOPPR. Presto iis a tool that ntegrates ...

Time June 24, 2026
arrow
Feature | X-Ray | Kyle Hardner

Water-window X-rays allow researchers to visualize biological cells at high contrast without staining agents or other ...

Time June 23, 2026
arrow
Subscribe Now